The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)

被引:131
作者
Dorato, MA [1 ]
Engelhardt, JA
机构
[1] Lilly Res Labs, Div Toxicol, Greenfield, IN 46140 USA
[2] Amgen Inc, Preclin Safety Assessement, Thousand Oaks, CA 91320 USA
关键词
adverse; toxicologically significant; biologically important; toxicologically relevant; margin of safety; hormesis; benchmark dose; no-observed-adverse-effect-level;
D O I
10.1016/j.yrtph.2005.05.004
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The no-observed-adverse-effect-level (NOAEL) is an important part of the non-clinical risk assessment. It is a professional opinion based on the design of the study, indication of the drug, expected pharmacology, and spectrum of off-target effects. There is no consistent standard definition of NOAEL. This is based, in part, on the varied definitions of what constitutes an adverse effect. Toxicologists, either investigating or reviewing, have not been consistent in defining an effect as either adverse or acceptable. The common definition of NOAEL, "the highest experimental point that is without adverse effect," serves us well in general discussions. It does not, however, address the interpretation of risk based on toxicologically relevant effects, nor does it consider the progression of effect with respect to duration and/or dose. This paper will discuss the issues and application of a functional definition of the NOAEL in toxicology evaluations. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 37 条
[1]  
[Anonymous], [No title captured]
[2]   Hormesis - An inappropriate extrapolation from the specific to the universal [J].
Axelrod, D ;
Burns, K ;
Davis, D ;
Von Larebeke, N .
INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2004, 10 (03) :335-339
[3]   REFERENCE DOSE (RFD) - DESCRIPTION AND USE IN HEALTH RISK ASSESSMENTS [J].
BARNES, DG ;
DOURSON, M .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1988, 8 (04) :471-486
[4]   IMPROVEMENTS IN QUANTITATIVE NONCANCER RISK ASSESSMENT [J].
BECK, BD ;
CONOLLY, RB ;
DOURSON, ML ;
GUTH, D ;
HATTIS, D ;
KIMMEL, C ;
LEWIS, SC .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1993, 20 (01) :1-14
[5]   Regulatory decision strategy for entry of a novel biologic therapeutic with a clinically unmonitorable toxicity into clinical trials: Pre-IND meetings and a case example [J].
Black, LE ;
Bendele, AM ;
Bendele, RA ;
Zack, PM ;
Hamilton, M .
TOXICOLOGIC PATHOLOGY, 1999, 27 (01) :22-26
[6]   IMPROVED METHOD FOR SELECTION OF THE NOAEL [J].
CALABRESE, EJ ;
BALDWIN, LA .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1994, 19 (01) :48-50
[7]   Hormesis - Basic, generalizable, central to toxicology and a method to improve the risk-assessment process [J].
Calabrese, EJ .
INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2004, 10 (04) :466-467
[8]   Hormesis: A highly generalizable and reproducible phenomenon with important implications for risk assessment [J].
Calabrese, EJ ;
Baldwin, LA ;
Holland, CD .
RISK ANALYSIS, 1999, 19 (02) :261-281
[9]   Toxicology rethinks its central belief - Hormesis demands a reappraisal of the way risks are assessed. [J].
Calabrese, EJ ;
Baldwin, LA .
NATURE, 2003, 421 (6924) :691-692
[10]   Hormesis as a biological hypothesis [J].
Calabrese, EJ ;
Baldwin, LA .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1998, 106 :357-362